Search News Archives
Special Offers and Promotions
IT Solutions and Laboratory Automation
Conferences | Events
Creoptix launches new WAVEcontrol software to deliver automated, flexible and intuitive label-free interaction analysis for biologics drug-discovery
Creoptix® (a Malvern Panalytical brand) is announcing the addition of two new wizards to their WAVEcontrol software to simplify and streamline workflows.
By combining the high sensitivity, throughput, and no-clog microfluidics of the WAVEsystem, with a faster, more flexible, automated approach to screening and characterization, Creoptix is accelerating biologics drug discovery and diagnostics development.
The WAVEsystem uses patented grating-coupled interferometry (GCI) technology as a powerful label-free alternative to conventional bioassays. Label-based analytics can cause issues such as altered analyte structures, non-specific binding, background noise and poor detection of weak interactions. GCI technology enables real-time affinity and kinetic measurement, with accurate binding specificity data for every type of analyte, from weak-binding fragments and small molecules to the most complex, native proteins in complex matrices.
The WAVEcontrol is the intuitive software used to operate the device and enables analysts to move from set-up to reporting in four simple steps, through an experiment design optimizer, automated set-up and flexible data evaluation, including Direct Kinetics, and customizable data reporting. The two new smart wizards being launched extend the automated capabilities of the system with:
Ligand screening – a faster, flexible way to screen and characterize antibodies. This wizard works in a Ligand Block logic with each automated block of activity including ligand capture, sample injection and surface regeneration. With an integrated Target Level function, ligand level density is automatically controlled for optimal comparison.
Calibration-free concentration analysis (CFCA) – a reliable, quick and easy calibration-free approach to the quantification of active protein concentration. This new feature is ideal for active protein characterization when a suitable calibrant is not available and when purification efficiency testing is required.
Tatiana Tiago, Product Manager at Creoptix, explains: “We wanted to create an environment where analysts could move seamlessly from sample to data in as few steps as possible, getting to the outputs they need at the touch of a button. The WAVEsystem already provides sensitivity and signal stability, fast throughput and non-clog fluidics, but we wanted to make sure that analysts could harness the analytical power of the system in an easy, flexible and automated way.”
“The new WAVEcontrol software wizards mirror the way scientists work and allow them to stay close to the ligand-analyte interaction but ensure as many tasks as possible are automated, saving time and cost, and reducing the errors that can creep in with manual processes.”
More information on how the WAVEsystem and the new smart wizards within WAVEcontrol are combining to deliver the best results for antibody screening, view our webinar, which includes a presentation from Global Access Diagnostics on how they are using the WAVEsystem and the new ligand screening functionality in lateral flow diagnostics development.
We draw on the power of our analytical instruments and services to make the invisible visible and the impossible possible.
Through the chemical, physical and structural analysis of materials, our high precision analytical systems and top-notch services support our customers in creating a better world. We help them improve everything from the energies that power us and the materials we build with, to the medicines that cure us and the foods we enjoy.
We partner with many of the world’s biggest companies, universities and research organizations. They value us not only for the power of our solutions, but also for the depth of our expertise, collaboration and integrity.
We are committed to Net Zero in our own operations by 2030 and in our total value chain by 2040. This is woven into the fabric of our business, and we help our employees and customers think about their part in creating a healthier, cleaner, and more productive world.
With over 2300 employees, we serve the world, and we are part of Spectris plc, the world leading precision measurement group. Malvern Panalytical. We’re BIG on small™.
Following integration in January 2022, Creoptix is a Malvern Panalytical brand. The team is headquartered in Wädenswil at the foot of the lake of Zurich in Switzerland, with US offices in the Boston area.
Creoptix enables life scientists to accelerate discovery by providing cutting-edge tools for molecular interaction analysis, with a focus on next-generation bioanalytical instruments for drug discovery and life sciences for both industry and academic research.
High sensitivity and resolution
Based on its proprietary biosensor, microfluidics and software technologies, the Creoptix WAVE provides exceptionally high sensitivity and resolution to study real-time biological interactions involving fragment, small molecules, peptides, membrane proteins, biologics and other molecules even in crude reaction mixtures and biofluids like undiluted serum and plasma.
Breakthrough level of kinetics analysis
The core Creoptix instrument is the WAVE. The Creoptix WAVE puts a breakthrough level of kinetics analysis at your fingertips by pushing the boundaries of affinity range and sample compatibility. The system’s exceptionally high data quality, sample compatibility and automated software facilitates drug discovery and enable new inroads into R&D. Creoptix also offer supporting chips and software for the instrument.